According to Agence France-Presse (AFP), researchers Emmanuel Mignot and Masashi Yanagisawa won the Albert-Lasker award for their independent discoveries uncovering the genetic and molecular causes of narcolepsy in the 1990s. Their parallel breakthroughs transformed sleep medicine and paved the way for new targeted therapies, including a treatment approved in the summer of 2026 across the United States, China, and Japan.
Albert-Lasker Award Honors 1990s Sleep Discoveries
The prestigious American prize celebrates foundational discoveries that solved the enigma of narcolepsy, a condition marked by sudden, uncontrollable sleep attacks and abrupt losses of muscle tone. According to AFP, the award recognizes the work of French researcher Emmanuel Mignot and Japanese researcher Masashi Yanagisawa. Often viewed as a predictor of a future Nobel Prize, the Lasker honor highlights how their separate research paths converged to reveal the biological roots of sleep disorders.
“Everything I did, people told me it was crazy,” Mignot told AFP, recalling his early efforts. Now a professor at Stanford University in California, he spent a decade examining canine genomes where narcolepsy is hereditary. Mignot successfully isolated the responsible gene in 1999.
Mapping Orexin and Canine Genetics
At the same time, Masashi Yanagisawa independently discovered orexin—also known as hypocretin—a neurotransmitter initially thought to regulate hunger, according to AFP. Yanagisawa found that a lack of this neurotransmitter causes narcolepsy in mice. “It was a scientific convergence that was both spectacular and magnificent,” Yanagisawa told AFP.
https://x.com/LaskerFDN/status/2097666515835228370
Combined, their findings clarified the underlying biological mechanism. In humans and mice, this neurotransmitter, normally produced in the hypothalamus at the base of the brain, is missing. In dogs, however, orexin is present, but a genetic mutation jams the molecular “lock” that the molecule needs to activate.
How Genetic Discoveries Transformed Sleep Medicine
Before these studies, the medical field rarely approached sleep through the lens of genetics and molecular biology, according to Yanagisawa. Early researchers relied on brain lesions to observe effects on sleep patterns. Mignot and Yanagisawa shifted the paradigm toward molecular analysis.
Did you know? Prior to the identification of orexin in the 1990s, sleep science relied heavily on observing brain lesion effects rather than mapping neurotransmitters and genetic mutations.
New Treatments Target Orexin Pathways
These breakthroughs led directly to pharmacological treatments for sleep disorders. According to AFP, the first medication targeting orexin deficiency in type 1 narcolepsy patients won approval in the summer of 2026 in the United States, China, and Japan.
“It really changes the game,” Mignot told AFP, noting that treated patients experience a radical transformation and regain the freedom to enjoy activities like dancing and playing hockey. Additionally, Yanagisawa explained that other treatments blocking orexin—which acts as a stimulant to maintain wakefulness—have been developed to help insomnia patients.
Frequently Asked Questions
What causes narcolepsy according to researchers?
According to AFP, research by Emmanuel Mignot and Masashi Yanagisawa shows that narcolepsy is caused by a deficiency or receptor blockage of orexin, a neurotransmitter produced in the hypothalamus.
When were the foundational orexin discoveries made?
The breakthrough findings were established during the 1990s through independent genetic and molecular research conducted by Emmanuel Mignot and Masashi Yanagisawa, according to AFP.
When was the first orexin-targeted narcolepsy treatment approved?
According to AFP, the first medication targeting orexin deficiency in type 1 narcolepsy was approved in the summer of 2026 in the United States, China, and Japan.
Join the Conversation
What are your thoughts on these modern advancements in sleep medicine? Share your experiences or questions in the comments below.
Keep reading